Discover the little-known medtech company that Zacks SCR has issued a price target of $32.50!
The medical device market is set to grow from over $500B to nearly $890B by 2032. Standing out in this fast-growing space is BioStem Technologies (OTC: BSEM), a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company is driving innovation in the wound care space and excitingly enhanced its intellectual property portfolio with the issuance of a significant patent. The is the first and only patent granted for use in tabular fenestrated allografts, which will support the company's commercial efforts and expand its IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as it advances in the market. Not only is BSEM reporting quarter after quarter of record revenues, but full year net revenue for 2024 is anticipated to be $301.8M, representing a stellar 1,702% growth since fiscal year 2023!
With a new clinical trial launched at the start of 2025 and the company gearing up to uplist to the NASDAQ exchange, it may be no surprise that BSEM has been given a $32.50 price target from Zacks Small Cap Research! The firm wrote in its last price target upgrade, "We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future. The vision management has for the company's products and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand. As such, we urge investors to take a good look at BSEM."
Will Zack up its price target on BSEM again?

This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $6,000.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with either Sideways Frequency or Huge Alerts. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM) .